Retatrutide vs Tesamorelin

A metabolic triple agonist versus a GHRH analogue. Here is how the two research peptides compare on class, format and price.

Retatrutide

Retatrutide is a synthetic peptide studied as a triple agonist at the GIP, GLP-1 and glucagon receptors. It is supplied lyophilised in a 10 mg vial for laboratory and in-vitro research use only.

As a triple agonist, Retatrutide is studied in metabolic research for activity across three receptor pathways, and is a common comparison point against the dual agonist Tirzepatide.

Tesamorelin

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. It is supplied lyophilised in a 10 mg vial for laboratory and in-vitro research use only.

Tesamorelin is studied for GHRH-receptor signalling in metabolic and growth-hormone research, and sits alongside CJC-1295 in the GHRH-analogue class.

Which do researchers choose?

Retatrutide and Tesamorelin are a metabolic triple agonist versus a GHRH analogue. The right choice depends on the research question: they differ in class (GGG triple receptor agonist vs GHRH analogue) and strength (10 mg vs 10 mg). Both are supplied lyophilised, third-party HPLC tested, and shipped express post Australia-wide for laboratory and in-vitro research use only.

Frequently asked questions